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Abstract 
A series of quinazolinone-based rhodanine-3-acetic acids was synthesized and 
tested for in vitro aldose reductase inhibitory activity. All the target compounds displayed 
nanomolar activity against the target enzyme. Compounds 3a, 3b, and 3e exhibited almost 
3-fold higher activity as compared to the only marketed reference drug epalrestat. 
Structure-activity relationship studies indicated that bulky substituents at the 3-phenyl ring 
of the quinazolinone moiety are generally not tolerated in the active site of the enzyme. 
Insertion of a methoxy group on the central benzylidene ring was found to have a variable 
effect on ALR-2 activity depending on the nature of peripheral quinazolinone ring 
substituents. Removal of the acetic acid moiety led to inactive or weakly active target 
compounds. Docking and Molecular dynamic simulations of the most active 2,4-
thiazolidinedione-3-acetic acid derivatives were also carried out, to provide the basis for 
further structure-guided design of novel inhibitors 
Key words: Rhodanine-3-acetic acids; aldose reductase inhibitors; molecular modeling. 
The incidence of diabetes mellitus has markedly increased over the last century due 
to changes in human life style and behavior.1 Estimates indicate that about 400 million 
patient worldwide are affected by diabetes and by the year 2030, about 10% of world 
population will suffer from this chronic disease.2 More importantly, the management of the 
debilitating complications associated with diabetes costs at least 10% of overall healthcare 
cost in many countries.3 For these reasons, the discovery and development of drugs for 
prevention and treatment of diabetic complications will remain a major challenge to 
medicinal chemists. In this context, there has been a growing interest over the last few 
decades in aldose reductase inhibitors as therapeutic candidates for diabetic 
complications.4-26 Aldose reductase (ALR-2) is the key enzyme of the polyol pathway 
through which glucose is metabolized under conditions of hyperglycemia associated with 
diabetes. In the polyol pathway, glucose is reduced by aldose reductase to sorbitol with the 
associated oxidation of NADPH to NADP. The accumulation of sorbitol in cells leads to 
osmotic stress. The second step in the polyol pathway involves the oxidation of sorbitol to 
fructose by the enzyme sorbitol dehydrogenase using NAD+ as a cofactor. Alteration of the 
proportion of cytosolic NADH to NAD+ results in reductive stress which is associated with 
reduced intracellular concentrations of glutathione, activation of protein kinase C, and non-
enzymatic glycation.27,28 Aldose reductase inhibitors are categorized into two major 
classes: acetic acid derivatives and the cyclic imides. The acetic acid derivatives currently 
available include epalrestat, tolrestat, zenarestat, and ponalrestat. The cyclic imides include 
the hydantoins and their bioisosteres such as the rhodanines, 2,4-thiazolidinediones, and 
the succinimides. Sorbinil, fidarestat, and imirestat are hydantoins whereas, ranirestat and 
minalrestat belong to the succinimides. (Chart 1). Unfortunately, many of these agents 
were unsuccessful in clinical trials due to poor pharmacokinetics, adverse effects, or low 
efficacy. Only epalrestat, which is a rhodanineacetic acid derivative, was approved for 
clinical use in Japan, China and India.29 Long-term studies have revealed that epalrestat is 
generally well tolerated with only mild side effects such as nausea, vomiting, and elevation 
of liver enzyme levels.16,30-34 These findings urged us to address novel rhodanineacetic acid 
derivatives as potential useful therapeutic candidates for the management of diabetic 
complications. In the present investigation, a series of quinazolinone-based 
rhodanineacetic acid derivatives was designed, synthesized, and tested for in vitro aldose 
reductase inhibitory activity.  Another series of representative rhodanines lacking the acetic 
acid moiety was also tested for comparison purposes.  
 
 
Chart 1.  Chemical structure of available aldose reductase inhibitors. 
 
A straightforward synthetic pathway was adopted to synthesize the target 
compounds as outlined in Scheme 1. The starting chloromethylquinazolinones (1a-h) were 
synthesized from anthranilic acid in two steps following reported procedures.35-38 The first 
step involves chloroacetylation of anthranilic acid using chloroacetyl chloride in dry 
benzene under reflux conditions. In the second step, cyclization to the desired 
chloromethylquinazolinones was achieved by direct reaction of the N-chloroacetyl 
anthranilic acid derivatives with the appropriate anilines in presence of phosphorous 
oxychloride as a condensing agent in dry toluene. Subsequently, 4-hydroxybenzaldehyde 
or vanillin was alkylated with the chloromethylquinazolinones (1a-h) in refluxing 
acetonitrile under the basic conditions of potassium carbonate and in the presence of 
potassium iodide to afford the aldehydes (2a-l) in good yields as previously reported by 
us.39 The title rhodanineacetic acids (3a-l) were obtained in fair yields via Knoevenagel-
type condensation of the aldehydes with rhodanine-3-acetic acid in refluxing acetic acid 
using β-alanine as a condensing agent. On the other hand, compounds 4a-g were obtained 
by condensation of the appropriate aldehyde with rhodanine in the presence of sodium 
acetate. Structures of all the target compounds were fully characterized by means of 1H and 
13C NMR spectroscopy and their purity were satisfactorily confirmed by elemental 
analysis.  
Scheme 1: 
 
 
Reagents and conditions: 
(a) Chloroacetyl chloride, benzene, reflux, 3h. (b) Substituted aniline, POCl3, toluene, 115 
ºC, 3h. (c) 4-Hydroxybenzaldehyde or vanillin, K2CO3, KI, acetonitrile, reflux, 3h. (d) 
Rhodanine-3-acetic acid, β-alanine, glacial acetic acid, 100 ºC, 3h. (e) Rhodanine, sodium 
acetate, glacial acetic acid, reflux, 24-48 h. 
 
All the novel synthesized compounds were tested in vitro for their aldose reductase 
inhibitory activity following standard protocols.40-43 The obtained IC50 values are reported 
in Table 1. Our investigation started by synthesizing and testing four compounds of the 
benzylidene series, namely 3a-3d. Their functional evaluation indicated that, moving from 
the hit 3a (IC50 60.9 nM), the presence of the electron-withdrawing fluoro atom on the 3-
phenyl ring of the quinazolinone core, as in 3b (IC50 55.6 nM), was tolerated while the 
presence of the bulkier bromo atom, as in 3c (IC50 711 nM), resulted in an almost 10-fold 
decrease of activity. Similarly, compound 3d (IC50 574 nM), having an electron-donating 
3-methyl substituent, turned out to be less active than the unsubstituted parent compound, 
3a. We than examined the effect on ALR-2 activity by inserting a 3-methoxy group on the 
central benzylidene ring. The hit compound of the novel series, namely 3e (IC50 49.7 nM) 
turned out to be slightly more active than the unsubstituted counterpart 3a (IC50 60.9 nM). 
On this basis, additional compounds of the 3-methoxybenzylidene series were synthesized 
and tested, bearing different electron-withdrawing and electron-donating substituents on 
the distal phenyl ring of the quinazolinone core. The observed functional data indicated 
that, regardless of both the type of the substituent and its position on the ring, peripheral 
substituents have a negative impact on ALR-2 activity. Actually, compared to the 
unsubstituted hit 3e (IC50 49.7 nM), all the substituted compounds (3f-l) showed IC50 
values in the low micromolar range, as shown in Table 1. To test the importance of the 
presence of an acetic acid moiety, a series of representative rhodanines 4a-g was 
synthesized as well, and tested for their ALR-2 activity. All the compounds of the novel 
series displayed no or weak activity against the target enzyme, as shown in Table 2.  
Table 1.  ALR2 inhibitory activities of rhodanine-3-acetic acid derivatives. 
 Ms 
Code 
R1 R2 IC50 (nM)a 
3a H H 60.9 
3b 4-F H 55.6 
3c 4-Br H 711 
3d 3-CH3 H 574 
3e H OCH3 49.7 
3f 4-F OCH3 358 
3g 3-Cl OCH3 419 
3h 4-Br OCH3 309 
3i 3-Br OCH3 401 
3j 4-CH3 OCH3 512 
3k 3-CH3 OCH3 329 
3l 4-CF3 OCH3 346 
Epalrestat - - 170 
aIC50 values, means, represent the concentration required to produce 50% enzyme 
inhibition. Errors ± 5% (from 3 different assays, data not shown). 
 
  
Table 2.  Percentage ALR2 inhibitory activities of rhodanine derivatives (4a-g). 
 
 
Code R1 R2 Percent inhibitiona 
4a H H 48.5%  
4b 4-F H 39.2%  
4c 4-Cl H n.a.b 
4d 4-Br H n.a.b 
4e 4-CH3 H n.a.b 
4f 4-OCH3 H 52.7%  
4g H OCH3 62.9%  
a The inhibitory effect was estimated at a concentration of 10 µM. bn.a = not active. 
 
To propose a structural binding mode of ALR2 when bound to the rhodanine-3-acetic acid 
derivatives, docking experiments were carried out on the newly synthesized compounds 
starting from the most active, 3e. It has been clearly proven that ALR2 can adopt different 
binding site conformations, depending on the structural characteristics of an inhibitor. To 
combat any computational bias, the target compound was docked into the binding pocket 
of the human ALR2/NADP+-IDD594 complex using the automated Autodock Vina plugin 
package in UCSF chimera.44,45 
Visual inspection of the docked pose with the best binding affinity (-11.05 k.cal/mol) 
(Figure 1), revealed 3e to bind favorably into the polar anion-binding pocket. Upon 
assessment of the residue-ligand interaction network, stabilizing hydrogen bond 
interactions were illustrated with residue Tyr48 and strong electrostatic interactions 
between 3e and the nicotinamide moiety of the NADP+ cofactor. The presence of the 
rhodanine ring is also shown to well orient the planar and aromatic quinazolinone 
fragments into the “specificity pocket”, thus creating favorable hydrophobic bonds with 
Leu300.  
These results validate the docked pose of the ALR2-3e complex in comparison to the 
docked complex of the ALR2-4c complex of which the 4c compound docked completely 
out of the binding pocket of ALR2. This concludes to that the removal of the acetic acid 
moiety leads to inactive or weakly active target compounds.  
 
 
Figure 1. Docked conformation of 3e in the active site of ALR2. A) Ligand carbon atoms are 
displayed in green and NADP+ in red. B) Ligand interaction and the binding mode of compound 
3e with aldose reductase receptor. The complex shows strong hydrogen bonds with TYR 48, HOH 
2062, HOH2131 at distance 2.08,3.07,2.8 A°. 
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Figure 2. Ligand interactions of compound 4c in complex with aldose reductase. The complex 
shows hydrogen bond interactions with HOH 2062, HOH2131 at distance 2.94, 3.22, 2.24A°. 
Molecular dynamics study is a significant tool to understand the stability and the binding 
mode of the ligand-receptor interactions. It also helps to understand the dynamics of the 
protein, which represent the true nature of protein better than ordinary docking, which does 
not completely consider the dynamic of protein.46 
The thermodynamic energy contribution of 3e to the total binding free energy of the 
complex surmounts to the stability of 3e in the ALR2 binding pocket and thus the stability 
of the complex during the simulation. Table 3 summarizes the free binding energy of the 
system. 
 Table 3: The free binding energy calculations of compound 3e Aldose Reductase complex 
during MD Using the MM-PBSA Method. 
 Δ EvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
Total 
Energy 
-79.26±0.148 -27.95±0.23 
-107.22± 
0.25 
46.21±0.149 
-61.00± 
0.196 
  
In conclusion, we described in this work a novel series of quinazolinone-based rhodanine-
3-acetic acid derivatives, developed as aldose reductase inhibitors. Tested in vitro against 
the target enzyme, they all proved to be active, showing IC50 values in the 
submicromolar/nanomolar range. Significantly, three out of the synthesized compounds, 
namely 3a, 3b, and 3e, turned out to be almost 3-fold more active than the reference drug, 
epalrestat. The acetic acid moiety of the compounds proved to be a key functional element 
as its removal, as in compounds 4a-g, resulted in a remarkable decrease of inhibitory 
efficacy. Docking studies performed on the most active compound helped to understand 
the binding mode of the synthesized derivatives, thus providing the basis for further 
structure-guided design hypotheses of novel analogues with higher efficacy. 
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